Go Deep
ADMA Biologics, Inc.
ADMA Biologics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,960 | 14.8 | 5.68 | 0.50 | 1,000.66 |
| Oct 2026 | 20,034 | 14.5 | 5.59 | 0.50 | 974.64 |
| Oct 2026 | 20,216 | 14.7 | 5.66 | 0.50 | 981.86 |
| Oct 2026 | 20,201 | 14.8 | 5.67 | 0.50 | 981.76 |
| Oct 2026 | 19,998 | 15.3 | 5.89 | 0.50 | 1,018.93 |
| Oct 2026 | 20,024 | 15.3 | 5.86 | 0.50 | 1,011.56 |
| Oct 2026 | 19,821 | 15.8 | 6.07 | 0.50 | 1,049.62 |
| Oct 2026 | 19,738 | 16.0 | 6.16 | 0.50 | 1,064.79 |
| Oct 2026 | 19,852 | 15.7 | 6.04 | 0.50 | 1,041.35 |
| Oct 2026 | 19,883 | 15.6 | 6.01 | 0.50 | 1,033.58 |
ADMA Biologics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 124,395,000.0 | 114,493,000.0 | 139,163,000.0 | 134,224,000.0 |
| Net Profit | 37,822,000.0 | 45,328,000.0 | 49,379,000.0 | 36,428,000.0 |
| EPS | 0.2 | 0.2 | 0.2 | 0.1 |
ADMA Biologics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 510,173,000.0 | 426,454,000.0 | 258,215,000.0 | 154,080,000.0 |
| Net Profit | 146,930,000.0 | 197,673,000.0 | -28,239,000.0 | -65,904,000.0 |
| EPS | 0.6 | 0.8 | -0.1 | -0.3 |
ADMA Biologics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 624,242,000.0 | 488,678,000.0 | 329,182,000.0 | 348,461,000.0 | — |
| Total Liabilities | 146,922,000.0 | 139,660,000.0 | 193,976,000.0 | 196,487,000.0 | — |
| Total Equity | 477,320,000.0 | 349,018,000.0 | 135,206,000.0 | 151,974,000.0 | — |
Owes vs Owns
ADMA Biologics, Inc. owed $0.40 for every $1 it owned in Jun 2026, down from $0.56 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.40× | 0.24× | 0.29× | 0.59× | 0.56× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ADMA Biologics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 14.0%Receivables 25.4%Inventory 33.1%Fixed assets (tangible) 11.5%Intangible assets 0.7%Other assets 15.4%
How it's funded — Dec 2025
Long-term debt 11.1%Payables 3.6%Other liabilities 8.4%Shareholders' equity 76.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 87.6 | 103.1 | 51.4 | 86.5 |
| Receivables | 158.4 | 50.0 | 27.4 | 15.5 |
| Inventory | 206.5 | 170.2 | 172.9 | 163.3 |
| Fixed assets (tangible) | 71.7 | 63.3 | 63.5 | 68.7 |
| Intangible assets | 4.2 | 4.0 | 4.0 | 4.5 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 95.8 | 98.0 | 10.0 | 9.9 |
| Liabilities & equity | ||||
| Short-term debt | 2.8 | 1.2 | 1.0 | 0.9 |
| Long-term debt | 69.3 | 72.3 | 130.6 | 142.8 |
| Payables | 22.5 | 20.2 | 15.7 | 13.2 |
| Other liabilities | 52.3 | 45.9 | 46.7 | 39.5 |
| Shareholders' equity | 477.3 | 349.0 | 135.2 | 152.0 |
| Net tangible assets | 473.2 | 345.0 | 131.2 | 147.4 |
ADMA Biologics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 50,396,000.0 | 118,672,000.0 | 8,800,000.0 | -59,508,000.0 | — |
| Investing Activities | -21,891,000.0 | -8,575,000.0 | -4,981,000.0 | -13,911,000.0 | — |
| Financing Activities | -44,022,000.0 | -58,302,000.0 | -38,989,000.0 | 108,852,000.0 | — |